nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—RET—epilepsy syndrome	0.408	1	CbGaD
Ruxolitinib—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.0092	0.0879	CbGbCtD
Ruxolitinib—CYP3A4—Felbamate—epilepsy syndrome	0.00856	0.0817	CbGbCtD
Ruxolitinib—CYP3A4—Trimethadione—epilepsy syndrome	0.00856	0.0817	CbGbCtD
Ruxolitinib—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00804	0.0768	CbGbCtD
Ruxolitinib—CYP3A4—Clonazepam—epilepsy syndrome	0.00727	0.0695	CbGbCtD
Ruxolitinib—CYP3A4—Clobazam—epilepsy syndrome	0.00697	0.0666	CbGbCtD
Ruxolitinib—CYP3A4—Rufinamide—epilepsy syndrome	0.00593	0.0566	CbGbCtD
Ruxolitinib—CYP3A4—Carbamazepine—epilepsy syndrome	0.00578	0.0552	CbGbCtD
Ruxolitinib—CYP3A4—Primidone—epilepsy syndrome	0.0054	0.0515	CbGbCtD
Ruxolitinib—CYP3A4—Phenytoin—epilepsy syndrome	0.00518	0.0495	CbGbCtD
Ruxolitinib—CYP3A4—Propofol—epilepsy syndrome	0.00483	0.0462	CbGbCtD
Ruxolitinib—CYP3A4—Acetazolamide—epilepsy syndrome	0.00462	0.0441	CbGbCtD
Ruxolitinib—CYP3A4—Phenobarbital—epilepsy syndrome	0.00462	0.0441	CbGbCtD
Ruxolitinib—CYP3A4—Midazolam—epilepsy syndrome	0.00456	0.0435	CbGbCtD
Ruxolitinib—CYP3A4—Diazepam—epilepsy syndrome	0.00438	0.0418	CbGbCtD
Ruxolitinib—CYP3A4—Zonisamide—epilepsy syndrome	0.00427	0.0408	CbGbCtD
Ruxolitinib—CYP3A4—Valproic Acid—epilepsy syndrome	0.00345	0.033	CbGbCtD
Ruxolitinib—CYP3A4—Topiramate—epilepsy syndrome	0.00312	0.0297	CbGbCtD
Ruxolitinib—PLK1—Pyrimethamine—Lamotrigine—epilepsy syndrome	0.00268	0.817	CbGdCrCtD
Ruxolitinib—PRKG2—nervous system—epilepsy syndrome	0.000665	0.0053	CbGeAlD
Ruxolitinib—HIPK2—forebrain—epilepsy syndrome	0.000657	0.00523	CbGeAlD
Ruxolitinib—PRKCE—head—epilepsy syndrome	0.000655	0.00521	CbGeAlD
Ruxolitinib—JAK1—telencephalon—epilepsy syndrome	0.000647	0.00515	CbGeAlD
Ruxolitinib—DCLK1—telencephalon—epilepsy syndrome	0.000647	0.00515	CbGeAlD
Ruxolitinib—PRKG2—central nervous system—epilepsy syndrome	0.00064	0.0051	CbGeAlD
Ruxolitinib—GRK1—nervous system—epilepsy syndrome	0.000634	0.00505	CbGeAlD
Ruxolitinib—PLK1—head—epilepsy syndrome	0.000629	0.00501	CbGeAlD
Ruxolitinib—RPS6KA6—head—epilepsy syndrome	0.000629	0.00501	CbGeAlD
Ruxolitinib—MAST1—head—epilepsy syndrome	0.000629	0.00501	CbGeAlD
Ruxolitinib—PRKCE—nervous system—epilepsy syndrome	0.000621	0.00494	CbGeAlD
Ruxolitinib—CAMK1—medulla oblongata—epilepsy syndrome	0.000619	0.00494	CbGeAlD
Ruxolitinib—DAPK2—telencephalon—epilepsy syndrome	0.000617	0.00491	CbGeAlD
Ruxolitinib—DYRK1A—brainstem—epilepsy syndrome	0.000612	0.00488	CbGeAlD
Ruxolitinib—GRK1—central nervous system—epilepsy syndrome	0.00061	0.00486	CbGeAlD
Ruxolitinib—BMPR2—brainstem—epilepsy syndrome	0.00061	0.00486	CbGeAlD
Ruxolitinib—ROCK1—forebrain—epilepsy syndrome	0.000606	0.00482	CbGeAlD
Ruxolitinib—HIPK2—telencephalon—epilepsy syndrome	0.000604	0.00481	CbGeAlD
Ruxolitinib—PRKCE—central nervous system—epilepsy syndrome	0.000597	0.00476	CbGeAlD
Ruxolitinib—RPS6KA6—nervous system—epilepsy syndrome	0.000596	0.00475	CbGeAlD
Ruxolitinib—PLK1—nervous system—epilepsy syndrome	0.000596	0.00475	CbGeAlD
Ruxolitinib—MAST1—nervous system—epilepsy syndrome	0.000596	0.00475	CbGeAlD
Ruxolitinib—DCLK3—head—epilepsy syndrome	0.000596	0.00475	CbGeAlD
Ruxolitinib—DYRK1A—forebrain—epilepsy syndrome	0.000591	0.00471	CbGeAlD
Ruxolitinib—BMPR2—forebrain—epilepsy syndrome	0.000588	0.00469	CbGeAlD
Ruxolitinib—PRKCE—cerebellum—epilepsy syndrome	0.000584	0.00465	CbGeAlD
Ruxolitinib—DAPK3—telencephalon—epilepsy syndrome	0.00058	0.00462	CbGeAlD
Ruxolitinib—RPS6KA6—central nervous system—epilepsy syndrome	0.000574	0.00457	CbGeAlD
Ruxolitinib—PLK1—central nervous system—epilepsy syndrome	0.000574	0.00457	CbGeAlD
Ruxolitinib—MAST1—central nervous system—epilepsy syndrome	0.000574	0.00457	CbGeAlD
Ruxolitinib—DCLK3—nervous system—epilepsy syndrome	0.000565	0.0045	CbGeAlD
Ruxolitinib—MAST1—cerebellum—epilepsy syndrome	0.000561	0.00447	CbGeAlD
Ruxolitinib—RPS6KA6—cerebellum—epilepsy syndrome	0.000561	0.00447	CbGeAlD
Ruxolitinib—ROCK1—telencephalon—epilepsy syndrome	0.000557	0.00444	CbGeAlD
Ruxolitinib—CAMK1—spinal cord—epilepsy syndrome	0.000552	0.0044	CbGeAlD
Ruxolitinib—CAMK2G—brainstem—epilepsy syndrome	0.000545	0.00435	CbGeAlD
Ruxolitinib—DCLK3—central nervous system—epilepsy syndrome	0.000544	0.00434	CbGeAlD
Ruxolitinib—DYRK1A—telencephalon—epilepsy syndrome	0.000543	0.00433	CbGeAlD
Ruxolitinib—BMPR2—telencephalon—epilepsy syndrome	0.000541	0.00431	CbGeAlD
Ruxolitinib—LRRK2—brainstem—epilepsy syndrome	0.000541	0.00431	CbGeAlD
Ruxolitinib—BMP2K—forebrain—epilepsy syndrome	0.000526	0.00419	CbGeAlD
Ruxolitinib—CAMK2G—forebrain—epilepsy syndrome	0.000526	0.00419	CbGeAlD
Ruxolitinib—PLK3—head—epilepsy syndrome	0.000525	0.00418	CbGeAlD
Ruxolitinib—LRRK2—forebrain—epilepsy syndrome	0.000522	0.00416	CbGeAlD
Ruxolitinib—JAK1—medulla oblongata—epilepsy syndrome	0.000508	0.00405	CbGeAlD
Ruxolitinib—DCLK1—medulla oblongata—epilepsy syndrome	0.000508	0.00405	CbGeAlD
Ruxolitinib—PRKG2—brain—epilepsy syndrome	0.000508	0.00405	CbGeAlD
Ruxolitinib—LTK—head—epilepsy syndrome	0.000507	0.00404	CbGeAlD
Ruxolitinib—PLK3—nervous system—epilepsy syndrome	0.000498	0.00396	CbGeAlD
Ruxolitinib—CAMK1D—medulla oblongata—epilepsy syndrome	0.000496	0.00395	CbGeAlD
Ruxolitinib—PHKG2—medulla oblongata—epilepsy syndrome	0.000493	0.00393	CbGeAlD
Ruxolitinib—CAMK1—head—epilepsy syndrome	0.000491	0.00391	CbGeAlD
Ruxolitinib—DAPK2—medulla oblongata—epilepsy syndrome	0.000485	0.00386	CbGeAlD
Ruxolitinib—GRK1—brain—epilepsy syndrome	0.000485	0.00386	CbGeAlD
Ruxolitinib—CAMK2G—telencephalon—epilepsy syndrome	0.000484	0.00386	CbGeAlD
Ruxolitinib—LRRK2—telencephalon—epilepsy syndrome	0.00048	0.00382	CbGeAlD
Ruxolitinib—PLK3—central nervous system—epilepsy syndrome	0.000479	0.00382	CbGeAlD
Ruxolitinib—MARK2—head—epilepsy syndrome	0.000477	0.0038	CbGeAlD
Ruxolitinib—PRKCE—brain—epilepsy syndrome	0.000474	0.00378	CbGeAlD
Ruxolitinib—CAMK1—nervous system—epilepsy syndrome	0.000465	0.00371	CbGeAlD
Ruxolitinib—JAK1—midbrain—epilepsy syndrome	0.000464	0.0037	CbGeAlD
Ruxolitinib—DCLK1—midbrain—epilepsy syndrome	0.000464	0.0037	CbGeAlD
Ruxolitinib—DAPK3—medulla oblongata—epilepsy syndrome	0.000456	0.00363	CbGeAlD
Ruxolitinib—RPS6KA6—brain—epilepsy syndrome	0.000456	0.00363	CbGeAlD
Ruxolitinib—PLK1—brain—epilepsy syndrome	0.000456	0.00363	CbGeAlD
Ruxolitinib—MAST1—brain—epilepsy syndrome	0.000456	0.00363	CbGeAlD
Ruxolitinib—JAK1—spinal cord—epilepsy syndrome	0.000453	0.00361	CbGeAlD
Ruxolitinib—DCLK1—spinal cord—epilepsy syndrome	0.000453	0.00361	CbGeAlD
Ruxolitinib—MARK2—nervous system—epilepsy syndrome	0.000452	0.0036	CbGeAlD
Ruxolitinib—CAMK1—central nervous system—epilepsy syndrome	0.000448	0.00357	CbGeAlD
Ruxolitinib—DAPK2—midbrain—epilepsy syndrome	0.000443	0.00353	CbGeAlD
Ruxolitinib—MAP3K2—telencephalon—epilepsy syndrome	0.00044	0.0035	CbGeAlD
Ruxolitinib—CAMK1—cerebellum—epilepsy syndrome	0.000438	0.00349	CbGeAlD
Ruxolitinib—MAP3K7—telencephalon—epilepsy syndrome	0.000435	0.00347	CbGeAlD
Ruxolitinib—MARK2—central nervous system—epilepsy syndrome	0.000435	0.00347	CbGeAlD
Ruxolitinib—DAPK2—spinal cord—epilepsy syndrome	0.000432	0.00344	CbGeAlD
Ruxolitinib—DCLK3—brain—epilepsy syndrome	0.000432	0.00344	CbGeAlD
Ruxolitinib—TYK2—telencephalon—epilepsy syndrome	0.000428	0.00341	CbGeAlD
Ruxolitinib—MARK2—cerebellum—epilepsy syndrome	0.000425	0.00339	CbGeAlD
Ruxolitinib—BMPR2—medulla oblongata—epilepsy syndrome	0.000425	0.00339	CbGeAlD
Ruxolitinib—JAK2—forebrain—epilepsy syndrome	0.000423	0.00337	CbGeAlD
Ruxolitinib—HIPK2—spinal cord—epilepsy syndrome	0.000423	0.00337	CbGeAlD
Ruxolitinib—MKNK2—telencephalon—epilepsy syndrome	0.000422	0.00336	CbGeAlD
Ruxolitinib—IRAK1—telencephalon—epilepsy syndrome	0.000422	0.00336	CbGeAlD
Ruxolitinib—DAPK3—midbrain—epilepsy syndrome	0.000417	0.00332	CbGeAlD
Ruxolitinib—DAPK3—spinal cord—epilepsy syndrome	0.000406	0.00324	CbGeAlD
Ruxolitinib—JAK3—head—epilepsy syndrome	0.000405	0.00323	CbGeAlD
Ruxolitinib—JAK1—head—epilepsy syndrome	0.000403	0.00321	CbGeAlD
Ruxolitinib—DCLK1—head—epilepsy syndrome	0.000403	0.00321	CbGeAlD
Ruxolitinib—TAOK2—cerebellum—epilepsy syndrome	0.000393	0.00313	CbGeAlD
Ruxolitinib—CAMK1D—head—epilepsy syndrome	0.000393	0.00313	CbGeAlD
Ruxolitinib—PHKG2—head—epilepsy syndrome	0.000391	0.00311	CbGeAlD
Ruxolitinib—JAK2—telencephalon—epilepsy syndrome	0.000389	0.0031	CbGeAlD
Ruxolitinib—BMPR2—midbrain—epilepsy syndrome	0.000388	0.00309	CbGeAlD
Ruxolitinib—TAOK3—brainstem—epilepsy syndrome	0.000385	0.00307	CbGeAlD
Ruxolitinib—JAK3—nervous system—epilepsy syndrome	0.000384	0.00306	CbGeAlD
Ruxolitinib—JAK1—nervous system—epilepsy syndrome	0.000382	0.00304	CbGeAlD
Ruxolitinib—DCLK1—nervous system—epilepsy syndrome	0.000382	0.00304	CbGeAlD
Ruxolitinib—CAMK2G—medulla oblongata—epilepsy syndrome	0.00038	0.00303	CbGeAlD
Ruxolitinib—PLK3—brain—epilepsy syndrome	0.00038	0.00303	CbGeAlD
Ruxolitinib—STK16—head—epilepsy syndrome	0.000378	0.00301	CbGeAlD
Ruxolitinib—LRRK2—medulla oblongata—epilepsy syndrome	0.000377	0.003	CbGeAlD
Ruxolitinib—HIPK2—head—epilepsy syndrome	0.000376	0.003	CbGeAlD
Ruxolitinib—CAMK1D—nervous system—epilepsy syndrome	0.000373	0.00297	CbGeAlD
Ruxolitinib—TAOK3—forebrain—epilepsy syndrome	0.000372	0.00296	CbGeAlD
Ruxolitinib—PHKG2—nervous system—epilepsy syndrome	0.00037	0.00295	CbGeAlD
Ruxolitinib—JAK3—central nervous system—epilepsy syndrome	0.00037	0.00295	CbGeAlD
Ruxolitinib—MAP3K19—head—epilepsy syndrome	0.000368	0.00293	CbGeAlD
Ruxolitinib—JAK1—central nervous system—epilepsy syndrome	0.000368	0.00293	CbGeAlD
Ruxolitinib—DCLK1—central nervous system—epilepsy syndrome	0.000368	0.00293	CbGeAlD
Ruxolitinib—LTK—brain—epilepsy syndrome	0.000367	0.00293	CbGeAlD
Ruxolitinib—JAK3—cerebellum—epilepsy syndrome	0.000362	0.00288	CbGeAlD
Ruxolitinib—DAPK3—head—epilepsy syndrome	0.000361	0.00288	CbGeAlD
Ruxolitinib—DCLK1—cerebellum—epilepsy syndrome	0.000359	0.00286	CbGeAlD
Ruxolitinib—JAK1—cerebellum—epilepsy syndrome	0.000359	0.00286	CbGeAlD
Ruxolitinib—CAMK1D—central nervous system—epilepsy syndrome	0.000359	0.00286	CbGeAlD
Ruxolitinib—STK16—nervous system—epilepsy syndrome	0.000358	0.00285	CbGeAlD
Ruxolitinib—CLK2—head—epilepsy syndrome	0.000358	0.00285	CbGeAlD
Ruxolitinib—PHKG2—central nervous system—epilepsy syndrome	0.000357	0.00284	CbGeAlD
Ruxolitinib—HIPK2—nervous system—epilepsy syndrome	0.000356	0.00284	CbGeAlD
Ruxolitinib—CAMK1—brain—epilepsy syndrome	0.000356	0.00283	CbGeAlD
Ruxolitinib—PLK1—Bortezomib—Lacosamide—epilepsy syndrome	0.000354	0.108	CbGdCrCtD
Ruxolitinib—CAMK1D—cerebellum—epilepsy syndrome	0.000351	0.00279	CbGeAlD
Ruxolitinib—MAP3K19—nervous system—epilepsy syndrome	0.000349	0.00278	CbGeAlD
Ruxolitinib—PHKG2—cerebellum—epilepsy syndrome	0.000349	0.00278	CbGeAlD
Ruxolitinib—BMP2K—midbrain—epilepsy syndrome	0.000348	0.00277	CbGeAlD
Ruxolitinib—CAMK2G—midbrain—epilepsy syndrome	0.000348	0.00277	CbGeAlD
Ruxolitinib—ROCK1—head—epilepsy syndrome	0.000347	0.00276	CbGeAlD
Ruxolitinib—MARK2—brain—epilepsy syndrome	0.000345	0.00275	CbGeAlD
Ruxolitinib—STK16—central nervous system—epilepsy syndrome	0.000345	0.00275	CbGeAlD
Ruxolitinib—LRRK2—midbrain—epilepsy syndrome	0.000345	0.00274	CbGeAlD
Ruxolitinib—HIPK2—central nervous system—epilepsy syndrome	0.000343	0.00273	CbGeAlD
Ruxolitinib—DAPK2—cerebellum—epilepsy syndrome	0.000343	0.00273	CbGeAlD
Ruxolitinib—DAPK3—nervous system—epilepsy syndrome	0.000342	0.00273	CbGeAlD
Ruxolitinib—MAP3K7—medulla oblongata—epilepsy syndrome	0.000342	0.00273	CbGeAlD
Ruxolitinib—TAOK3—telencephalon—epilepsy syndrome	0.000342	0.00272	CbGeAlD
Ruxolitinib—CLK2—nervous system—epilepsy syndrome	0.000339	0.0027	CbGeAlD
Ruxolitinib—BMP2K—spinal cord—epilepsy syndrome	0.000339	0.0027	CbGeAlD
Ruxolitinib—CAMK2G—spinal cord—epilepsy syndrome	0.000339	0.0027	CbGeAlD
Ruxolitinib—DYRK1A—head—epilepsy syndrome	0.000338	0.00269	CbGeAlD
Ruxolitinib—STK16—cerebellum—epilepsy syndrome	0.000337	0.00269	CbGeAlD
Ruxolitinib—BMPR2—head—epilepsy syndrome	0.000337	0.00268	CbGeAlD
Ruxolitinib—MAP3K19—central nervous system—epilepsy syndrome	0.000336	0.00268	CbGeAlD
Ruxolitinib—LRRK2—spinal cord—epilepsy syndrome	0.000336	0.00268	CbGeAlD
Ruxolitinib—TYK2—medulla oblongata—epilepsy syndrome	0.000336	0.00268	CbGeAlD
Ruxolitinib—HIPK2—cerebellum—epilepsy syndrome	0.000335	0.00267	CbGeAlD
Ruxolitinib—MKNK2—medulla oblongata—epilepsy syndrome	0.000332	0.00264	CbGeAlD
Ruxolitinib—DAPK3—central nervous system—epilepsy syndrome	0.00033	0.00263	CbGeAlD
Ruxolitinib—ROCK1—nervous system—epilepsy syndrome	0.000329	0.00262	CbGeAlD
Ruxolitinib—CLK2—central nervous system—epilepsy syndrome	0.000327	0.0026	CbGeAlD
Ruxolitinib—RET—medulla oblongata—epilepsy syndrome	0.000323	0.00258	CbGeAlD
Ruxolitinib—DAPK3—cerebellum—epilepsy syndrome	0.000322	0.00257	CbGeAlD
Ruxolitinib—DYRK1A—nervous system—epilepsy syndrome	0.000321	0.00255	CbGeAlD
Ruxolitinib—TAOK2—brain—epilepsy syndrome	0.00032	0.00255	CbGeAlD
Ruxolitinib—BMPR2—nervous system—epilepsy syndrome	0.000319	0.00254	CbGeAlD
Ruxolitinib—CLK2—cerebellum—epilepsy syndrome	0.000319	0.00254	CbGeAlD
Ruxolitinib—ROCK1—central nervous system—epilepsy syndrome	0.000317	0.00252	CbGeAlD
Ruxolitinib—MAP3K7—midbrain—epilepsy syndrome	0.000313	0.00249	CbGeAlD
Ruxolitinib—DYRK1A—central nervous system—epilepsy syndrome	0.000309	0.00246	CbGeAlD
Ruxolitinib—BMPR2—central nervous system—epilepsy syndrome	0.000307	0.00245	CbGeAlD
Ruxolitinib—TYK2—midbrain—epilepsy syndrome	0.000307	0.00245	CbGeAlD
Ruxolitinib—JAK2—medulla oblongata—epilepsy syndrome	0.000306	0.00244	CbGeAlD
Ruxolitinib—MAP3K7—spinal cord—epilepsy syndrome	0.000305	0.00243	CbGeAlD
Ruxolitinib—MKNK2—midbrain—epilepsy syndrome	0.000303	0.00241	CbGeAlD
Ruxolitinib—IRAK1—midbrain—epilepsy syndrome	0.000303	0.00241	CbGeAlD
Ruxolitinib—DYRK1A—cerebellum—epilepsy syndrome	0.000302	0.0024	CbGeAlD
Ruxolitinib—CAMK2G—head—epilepsy syndrome	0.000301	0.0024	CbGeAlD
Ruxolitinib—BMP2K—head—epilepsy syndrome	0.000301	0.0024	CbGeAlD
Ruxolitinib—BMPR2—cerebellum—epilepsy syndrome	0.000301	0.00239	CbGeAlD
Ruxolitinib—TYK2—spinal cord—epilepsy syndrome	0.0003	0.00239	CbGeAlD
Ruxolitinib—LRRK2—head—epilepsy syndrome	0.000299	0.00238	CbGeAlD
Ruxolitinib—Nervous system disorder—Levetiracetam—epilepsy syndrome	0.000296	0.00205	CcSEcCtD
Ruxolitinib—Weight decreased—Valproic Acid—epilepsy syndrome	0.000296	0.00205	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Levetiracetam—epilepsy syndrome	0.000296	0.00205	CcSEcCtD
Ruxolitinib—MKNK2—spinal cord—epilepsy syndrome	0.000296	0.00236	CbGeAlD
Ruxolitinib—RET—midbrain—epilepsy syndrome	0.000296	0.00236	CbGeAlD
Ruxolitinib—MAP3K3—medulla oblongata—epilepsy syndrome	0.000295	0.00235	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Vigabatrin—epilepsy syndrome	0.000294	0.00204	CcSEcCtD
Ruxolitinib—JAK3—brain—epilepsy syndrome	0.000294	0.00234	CbGeAlD
Ruxolitinib—Skin disorder—Levetiracetam—epilepsy syndrome	0.000293	0.00204	CcSEcCtD
Ruxolitinib—Pruritus—Rufinamide—epilepsy syndrome	0.000293	0.00203	CcSEcCtD
Ruxolitinib—DCLK1—brain—epilepsy syndrome	0.000292	0.00232	CbGeAlD
Ruxolitinib—JAK1—brain—epilepsy syndrome	0.000292	0.00232	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Acetazolamide—epilepsy syndrome	0.000291	0.00202	CcSEcCtD
Ruxolitinib—Fatigue—Acetazolamide—epilepsy syndrome	0.00029	0.00201	CcSEcCtD
Ruxolitinib—PLK4—brain—epilepsy syndrome	0.00029	0.00231	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Diazepam—epilepsy syndrome	0.00029	0.00201	CcSEcCtD
Ruxolitinib—Infection—Fosphenytoin—epilepsy syndrome	0.00029	0.00201	CcSEcCtD
Ruxolitinib—Anaemia—Clonazepam—epilepsy syndrome	0.000289	0.00201	CcSEcCtD
Ruxolitinib—RET—spinal cord—epilepsy syndrome	0.000288	0.0023	CbGeAlD
Ruxolitinib—Anaemia—Phenytoin—epilepsy syndrome	0.000287	0.00199	CcSEcCtD
Ruxolitinib—NUAK2—cerebellum—epilepsy syndrome	0.000287	0.00229	CbGeAlD
Ruxolitinib—Malnutrition—Lamotrigine—epilepsy syndrome	0.000287	0.00199	CcSEcCtD
Ruxolitinib—BMP2K—nervous system—epilepsy syndrome	0.000286	0.00228	CbGeAlD
Ruxolitinib—CAMK2G—nervous system—epilepsy syndrome	0.000286	0.00228	CbGeAlD
Ruxolitinib—Thrombocytopenia—Fosphenytoin—epilepsy syndrome	0.000285	0.00198	CcSEcCtD
Ruxolitinib—CAMK1D—brain—epilepsy syndrome	0.000285	0.00227	CbGeAlD
Ruxolitinib—Urinary tract infection—Valproic Acid—epilepsy syndrome	0.000283	0.00197	CcSEcCtD
Ruxolitinib—LRRK2—nervous system—epilepsy syndrome	0.000283	0.00226	CbGeAlD
Ruxolitinib—PHKG2—brain—epilepsy syndrome	0.000283	0.00226	CbGeAlD
Ruxolitinib—Flatulence—Lamotrigine—epilepsy syndrome	0.000283	0.00196	CcSEcCtD
Ruxolitinib—Infection—Vigabatrin—epilepsy syndrome	0.000282	0.00196	CcSEcCtD
Ruxolitinib—Pancytopenia—Pregabalin—epilepsy syndrome	0.000281	0.00195	CcSEcCtD
Ruxolitinib—Asthenia—Lacosamide—epilepsy syndrome	0.000279	0.00194	CcSEcCtD
Ruxolitinib—Dizziness—Phenobarbital—epilepsy syndrome	0.000279	0.00194	CcSEcCtD
Ruxolitinib—Nervous system disorder—Vigabatrin—epilepsy syndrome	0.000279	0.00193	CcSEcCtD
Ruxolitinib—DAPK2—brain—epilepsy syndrome	0.000278	0.00222	CbGeAlD
Ruxolitinib—Infection—Diazepam—epilepsy syndrome	0.000278	0.00193	CcSEcCtD
Ruxolitinib—Neutropenia—Pregabalin—epilepsy syndrome	0.000276	0.00192	CcSEcCtD
Ruxolitinib—Skin disorder—Vigabatrin—epilepsy syndrome	0.000276	0.00191	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Valproic Acid—epilepsy syndrome	0.000276	0.00191	CcSEcCtD
Ruxolitinib—Pruritus—Lacosamide—epilepsy syndrome	0.000275	0.00191	CcSEcCtD
Ruxolitinib—BMP2K—central nervous system—epilepsy syndrome	0.000275	0.00219	CbGeAlD
Ruxolitinib—CAMK2G—central nervous system—epilepsy syndrome	0.000275	0.00219	CbGeAlD
Ruxolitinib—Epistaxis—Valproic Acid—epilepsy syndrome	0.000275	0.00191	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Zonisamide—epilepsy syndrome	0.000275	0.0019	CcSEcCtD
Ruxolitinib—Nervous system disorder—Diazepam—epilepsy syndrome	0.000274	0.0019	CcSEcCtD
Ruxolitinib—Anaemia—Carbamazepine—epilepsy syndrome	0.000274	0.0019	CcSEcCtD
Ruxolitinib—Dizziness—Rufinamide—epilepsy syndrome	0.000274	0.0019	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Diazepam—epilepsy syndrome	0.000274	0.0019	CcSEcCtD
Ruxolitinib—STK16—brain—epilepsy syndrome	0.000274	0.00218	CbGeAlD
Ruxolitinib—MAP3K2—head—epilepsy syndrome	0.000274	0.00218	CbGeAlD
Ruxolitinib—LRRK2—central nervous system—epilepsy syndrome	0.000273	0.00217	CbGeAlD
Ruxolitinib—JAK2—spinal cord—epilepsy syndrome	0.000273	0.00217	CbGeAlD
Ruxolitinib—HIPK2—brain—epilepsy syndrome	0.000272	0.00217	CbGeAlD
Ruxolitinib—Skin disorder—Diazepam—epilepsy syndrome	0.000272	0.00188	CcSEcCtD
Ruxolitinib—Asthenia—Clobazam—epilepsy syndrome	0.000271	0.00188	CcSEcCtD
Ruxolitinib—Fatigue—Propofol—epilepsy syndrome	0.00027	0.00187	CcSEcCtD
Ruxolitinib—MAP3K3—midbrain—epilepsy syndrome	0.000269	0.00215	CbGeAlD
Ruxolitinib—Weight increased—Pregabalin—epilepsy syndrome	0.000269	0.00187	CcSEcCtD
Ruxolitinib—Infection—Felbamate—epilepsy syndrome	0.000269	0.00187	CcSEcCtD
Ruxolitinib—CAMK2G—cerebellum—epilepsy syndrome	0.000269	0.00214	CbGeAlD
Ruxolitinib—BMP2K—cerebellum—epilepsy syndrome	0.000269	0.00214	CbGeAlD
Ruxolitinib—TAOK3—medulla oblongata—epilepsy syndrome	0.000269	0.00214	CbGeAlD
Ruxolitinib—Weight decreased—Pregabalin—epilepsy syndrome	0.000267	0.00186	CcSEcCtD
Ruxolitinib—Pruritus—Clobazam—epilepsy syndrome	0.000267	0.00185	CcSEcCtD
Ruxolitinib—MAP3K19—brain—epilepsy syndrome	0.000267	0.00213	CbGeAlD
Ruxolitinib—LRRK2—cerebellum—epilepsy syndrome	0.000267	0.00212	CbGeAlD
Ruxolitinib—TYK2—head—epilepsy syndrome	0.000266	0.00212	CbGeAlD
Ruxolitinib—Body temperature increased—Acetazolamide—epilepsy syndrome	0.000266	0.00185	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Felbamate—epilepsy syndrome	0.000265	0.00184	CcSEcCtD
Ruxolitinib—Anaemia—Lamotrigine—epilepsy syndrome	0.000265	0.00184	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Clonazepam—epilepsy syndrome	0.000265	0.00184	CcSEcCtD
Ruxolitinib—Headache—Phenobarbital—epilepsy syndrome	0.000264	0.00183	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Midazolam—epilepsy syndrome	0.000264	0.00183	CcSEcCtD
Ruxolitinib—Fatigue—Midazolam—epilepsy syndrome	0.000264	0.00183	CcSEcCtD
Ruxolitinib—Infestation—Pregabalin—epilepsy syndrome	0.000264	0.00183	CcSEcCtD
Ruxolitinib—Infestation NOS—Pregabalin—epilepsy syndrome	0.000264	0.00183	CcSEcCtD
Ruxolitinib—Infection—Zonisamide—epilepsy syndrome	0.000263	0.00183	CcSEcCtD
Ruxolitinib—Haemoglobin—Valproic Acid—epilepsy syndrome	0.000263	0.00183	CcSEcCtD
Ruxolitinib—MKNK2—head—epilepsy syndrome	0.000263	0.00209	CbGeAlD
Ruxolitinib—MAP3K3—spinal cord—epilepsy syndrome	0.000263	0.00209	CbGeAlD
Ruxolitinib—Haemorrhage—Valproic Acid—epilepsy syndrome	0.000262	0.00182	CcSEcCtD
Ruxolitinib—DAPK3—brain—epilepsy syndrome	0.000262	0.00209	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Oxcarbazepine—epilepsy syndrome	0.000261	0.00181	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Levetiracetam—epilepsy syndrome	0.000261	0.00181	CcSEcCtD
Ruxolitinib—Fatigue—Levetiracetam—epilepsy syndrome	0.00026	0.00181	CcSEcCtD
Ruxolitinib—Nervous system disorder—Zonisamide—epilepsy syndrome	0.00026	0.0018	CcSEcCtD
Ruxolitinib—Headache—Rufinamide—epilepsy syndrome	0.00026	0.0018	CcSEcCtD
Ruxolitinib—MAP3K2—nervous system—epilepsy syndrome	0.00026	0.00207	CbGeAlD
Ruxolitinib—Thrombocytopenia—Zonisamide—epilepsy syndrome	0.000259	0.0018	CcSEcCtD
Ruxolitinib—CLK2—brain—epilepsy syndrome	0.000259	0.00207	CbGeAlD
Ruxolitinib—Skin disorder—Zonisamide—epilepsy syndrome	0.000257	0.00179	CcSEcCtD
Ruxolitinib—Dizziness—Lacosamide—epilepsy syndrome	0.000257	0.00178	CcSEcCtD
Ruxolitinib—RET—head—epilepsy syndrome	0.000256	0.00204	CbGeAlD
Ruxolitinib—Urinary tract infection—Pregabalin—epilepsy syndrome	0.000256	0.00178	CcSEcCtD
Ruxolitinib—Infection—Clonazepam—epilepsy syndrome	0.000254	0.00176	CcSEcCtD
Ruxolitinib—TYK2—nervous system—epilepsy syndrome	0.000252	0.00201	CbGeAlD
Ruxolitinib—Infection—Phenytoin—epilepsy syndrome	0.000252	0.00175	CcSEcCtD
Ruxolitinib—Haematuria—Pregabalin—epilepsy syndrome	0.000251	0.00174	CcSEcCtD
Ruxolitinib—ROCK1—brain—epilepsy syndrome	0.000251	0.002	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Carbamazepine—epilepsy syndrome	0.000251	0.00174	CcSEcCtD
Ruxolitinib—Infection—Oxcarbazepine—epilepsy syndrome	0.000251	0.00174	CcSEcCtD
Ruxolitinib—Nervous system disorder—Clonazepam—epilepsy syndrome	0.00025	0.00174	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Clonazepam—epilepsy syndrome	0.00025	0.00173	CcSEcCtD
Ruxolitinib—MAP3K2—central nervous system—epilepsy syndrome	0.00025	0.00199	CbGeAlD
Ruxolitinib—Dizziness—Clobazam—epilepsy syndrome	0.00025	0.00173	CcSEcCtD
Ruxolitinib—MKNK2—nervous system—epilepsy syndrome	0.000249	0.00199	CbGeAlD
Ruxolitinib—Nervous system disorder—Phenytoin—epilepsy syndrome	0.000249	0.00173	CcSEcCtD
Ruxolitinib—Epistaxis—Pregabalin—epilepsy syndrome	0.000249	0.00173	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Phenytoin—epilepsy syndrome	0.000248	0.00172	CcSEcCtD
Ruxolitinib—Skin disorder—Clonazepam—epilepsy syndrome	0.000248	0.00172	CcSEcCtD
Ruxolitinib—Nervous system disorder—Oxcarbazepine—epilepsy syndrome	0.000247	0.00172	CcSEcCtD
Ruxolitinib—Body temperature increased—Propofol—epilepsy syndrome	0.000247	0.00171	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Oxcarbazepine—epilepsy syndrome	0.000247	0.00171	CcSEcCtD
Ruxolitinib—Weight increased—Gabapentin—epilepsy syndrome	0.000247	0.00171	CcSEcCtD
Ruxolitinib—TAOK3—midbrain—epilepsy syndrome	0.000245	0.00196	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Vigabatrin—epilepsy syndrome	0.000245	0.0017	CcSEcCtD
Ruxolitinib—Weight decreased—Gabapentin—epilepsy syndrome	0.000245	0.0017	CcSEcCtD
Ruxolitinib—Skin disorder—Oxcarbazepine—epilepsy syndrome	0.000245	0.0017	CcSEcCtD
Ruxolitinib—PLK1—Niclosamide—Clonazepam—epilepsy syndrome	0.000245	0.0748	CbGdCrCtD
Ruxolitinib—DYRK1A—brain—epilepsy syndrome	0.000245	0.00195	CbGeAlD
Ruxolitinib—Fatigue—Vigabatrin—epilepsy syndrome	0.000245	0.0017	CcSEcCtD
Ruxolitinib—MAP3K2—cerebellum—epilepsy syndrome	0.000244	0.00195	CbGeAlD
Ruxolitinib—BMPR2—brain—epilepsy syndrome	0.000244	0.00194	CbGeAlD
Ruxolitinib—Headache—Lacosamide—epilepsy syndrome	0.000244	0.00169	CcSEcCtD
Ruxolitinib—TYK2—central nervous system—epilepsy syndrome	0.000243	0.00194	CbGeAlD
Ruxolitinib—RET—nervous system—epilepsy syndrome	0.000243	0.00194	CbGeAlD
Ruxolitinib—JAK2—head—epilepsy syndrome	0.000242	0.00193	CbGeAlD
Ruxolitinib—MAP3K7—cerebellum—epilepsy syndrome	0.000242	0.00193	CbGeAlD
Ruxolitinib—Infestation—Gabapentin—epilepsy syndrome	0.000242	0.00168	CcSEcCtD
Ruxolitinib—Infestation NOS—Gabapentin—epilepsy syndrome	0.000242	0.00168	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Diazepam—epilepsy syndrome	0.000241	0.00168	CcSEcCtD
Ruxolitinib—Asthenia—Acetazolamide—epilepsy syndrome	0.000241	0.00168	CcSEcCtD
Ruxolitinib—Fatigue—Diazepam—epilepsy syndrome	0.000241	0.00167	CcSEcCtD
Ruxolitinib—Infection—Carbamazepine—epilepsy syndrome	0.000241	0.00167	CcSEcCtD
Ruxolitinib—MKNK2—central nervous system—epilepsy syndrome	0.00024	0.00191	CbGeAlD
Ruxolitinib—TAOK3—spinal cord—epilepsy syndrome	0.00024	0.00191	CbGeAlD
Ruxolitinib—Body temperature increased—Levetiracetam—epilepsy syndrome	0.000239	0.00166	CcSEcCtD
Ruxolitinib—Haemoglobin—Pregabalin—epilepsy syndrome	0.000238	0.00165	CcSEcCtD
Ruxolitinib—TYK2—cerebellum—epilepsy syndrome	0.000238	0.00189	CbGeAlD
Ruxolitinib—Nervous system disorder—Carbamazepine—epilepsy syndrome	0.000237	0.00165	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Carbamazepine—epilepsy syndrome	0.000237	0.00164	CcSEcCtD
Ruxolitinib—Haemorrhage—Pregabalin—epilepsy syndrome	0.000237	0.00164	CcSEcCtD
Ruxolitinib—Headache—Clobazam—epilepsy syndrome	0.000237	0.00164	CcSEcCtD
Ruxolitinib—Skin disorder—Carbamazepine—epilepsy syndrome	0.000235	0.00163	CcSEcCtD
Ruxolitinib—Urinary tract infection—Gabapentin—epilepsy syndrome	0.000235	0.00163	CcSEcCtD
Ruxolitinib—MKNK2—cerebellum—epilepsy syndrome	0.000234	0.00187	CbGeAlD
Ruxolitinib—IRAK1—cerebellum—epilepsy syndrome	0.000234	0.00187	CbGeAlD
Ruxolitinib—RET—central nervous system—epilepsy syndrome	0.000234	0.00186	CbGeAlD
Ruxolitinib—MAP3K3—head—epilepsy syndrome	0.000233	0.00186	CbGeAlD
Ruxolitinib—Fatigue—Felbamate—epilepsy syndrome	0.000233	0.00162	CcSEcCtD
Ruxolitinib—NUAK2—brain—epilepsy syndrome	0.000233	0.00186	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Topiramate—epilepsy syndrome	0.000233	0.00161	CcSEcCtD
Ruxolitinib—Infection—Lamotrigine—epilepsy syndrome	0.000233	0.00161	CcSEcCtD
Ruxolitinib—Haematuria—Gabapentin—epilepsy syndrome	0.00023	0.0016	CcSEcCtD
Ruxolitinib—Body temperature increased—Fosphenytoin—epilepsy syndrome	0.00023	0.0016	CcSEcCtD
Ruxolitinib—JAK2—nervous system—epilepsy syndrome	0.00023	0.00183	CbGeAlD
Ruxolitinib—Nervous system disorder—Lamotrigine—epilepsy syndrome	0.00023	0.00159	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Lamotrigine—epilepsy syndrome	0.000229	0.00159	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Zonisamide—epilepsy syndrome	0.000229	0.00159	CcSEcCtD
Ruxolitinib—RET—cerebellum—epilepsy syndrome	0.000229	0.00182	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Gabapentin—epilepsy syndrome	0.000229	0.00159	CcSEcCtD
Ruxolitinib—Fatigue—Zonisamide—epilepsy syndrome	0.000228	0.00159	CcSEcCtD
Ruxolitinib—Epistaxis—Gabapentin—epilepsy syndrome	0.000228	0.00158	CcSEcCtD
Ruxolitinib—Malnutrition—Valproic Acid—epilepsy syndrome	0.000228	0.00158	CcSEcCtD
Ruxolitinib—Body temperature increased—Vigabatrin—epilepsy syndrome	0.000225	0.00156	CcSEcCtD
Ruxolitinib—Flatulence—Valproic Acid—epilepsy syndrome	0.000225	0.00156	CcSEcCtD
Ruxolitinib—Asthenia—Propofol—epilepsy syndrome	0.000224	0.00156	CcSEcCtD
Ruxolitinib—Dizziness—Acetazolamide—epilepsy syndrome	0.000223	0.00154	CcSEcCtD
Ruxolitinib—MAP3K3—nervous system—epilepsy syndrome	0.000221	0.00176	CbGeAlD
Ruxolitinib—Pruritus—Propofol—epilepsy syndrome	0.000221	0.00153	CcSEcCtD
Ruxolitinib—JAK2—central nervous system—epilepsy syndrome	0.000221	0.00176	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Clonazepam—epilepsy syndrome	0.000221	0.00153	CcSEcCtD
Ruxolitinib—Fatigue—Clonazepam—epilepsy syndrome	0.00022	0.00153	CcSEcCtD
Ruxolitinib—Asthenia—Midazolam—epilepsy syndrome	0.000219	0.00152	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Phenytoin—epilepsy syndrome	0.000219	0.00152	CcSEcCtD
Ruxolitinib—Fatigue—Phenytoin—epilepsy syndrome	0.000219	0.00152	CcSEcCtD
Ruxolitinib—CAMK2G—brain—epilepsy syndrome	0.000218	0.00174	CbGeAlD
Ruxolitinib—BMP2K—brain—epilepsy syndrome	0.000218	0.00174	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Oxcarbazepine—epilepsy syndrome	0.000218	0.00151	CcSEcCtD
Ruxolitinib—Fatigue—Oxcarbazepine—epilepsy syndrome	0.000218	0.00151	CcSEcCtD
Ruxolitinib—Haemorrhage—Gabapentin—epilepsy syndrome	0.000217	0.00151	CcSEcCtD
Ruxolitinib—Asthenia—Levetiracetam—epilepsy syndrome	0.000217	0.0015	CcSEcCtD
Ruxolitinib—Pancytopenia—Topiramate—epilepsy syndrome	0.000217	0.0015	CcSEcCtD
Ruxolitinib—LRRK2—brain—epilepsy syndrome	0.000216	0.00172	CbGeAlD
Ruxolitinib—Pruritus—Midazolam—epilepsy syndrome	0.000216	0.0015	CcSEcCtD
Ruxolitinib—JAK2—cerebellum—epilepsy syndrome	0.000216	0.00172	CbGeAlD
Ruxolitinib—Body temperature increased—Felbamate—epilepsy syndrome	0.000214	0.00148	CcSEcCtD
Ruxolitinib—Pruritus—Levetiracetam—epilepsy syndrome	0.000214	0.00148	CcSEcCtD
Ruxolitinib—Neutropenia—Topiramate—epilepsy syndrome	0.000213	0.00148	CcSEcCtD
Ruxolitinib—MAP3K3—central nervous system—epilepsy syndrome	0.000213	0.0017	CbGeAlD
Ruxolitinib—TAOK3—head—epilepsy syndrome	0.000213	0.0017	CbGeAlD
Ruxolitinib—Headache—Acetazolamide—epilepsy syndrome	0.000211	0.00146	CcSEcCtD
Ruxolitinib—Anaemia—Valproic Acid—epilepsy syndrome	0.000211	0.00146	CcSEcCtD
Ruxolitinib—Body temperature increased—Zonisamide—epilepsy syndrome	0.000209	0.00145	CcSEcCtD
Ruxolitinib—Asthenia—Fosphenytoin—epilepsy syndrome	0.000209	0.00145	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Carbamazepine—epilepsy syndrome	0.000209	0.00145	CcSEcCtD
Ruxolitinib—Fatigue—Carbamazepine—epilepsy syndrome	0.000209	0.00145	CcSEcCtD
Ruxolitinib—MAP3K3—cerebellum—epilepsy syndrome	0.000208	0.00166	CbGeAlD
Ruxolitinib—Weight increased—Topiramate—epilepsy syndrome	0.000208	0.00144	CcSEcCtD
Ruxolitinib—Dizziness—Propofol—epilepsy syndrome	0.000207	0.00143	CcSEcCtD
Ruxolitinib—Weight decreased—Topiramate—epilepsy syndrome	0.000206	0.00143	CcSEcCtD
Ruxolitinib—Pruritus—Fosphenytoin—epilepsy syndrome	0.000206	0.00143	CcSEcCtD
Ruxolitinib—Malnutrition—Pregabalin—epilepsy syndrome	0.000206	0.00143	CcSEcCtD
Ruxolitinib—Asthenia—Vigabatrin—epilepsy syndrome	0.000204	0.00141	CcSEcCtD
Ruxolitinib—Infestation NOS—Topiramate—epilepsy syndrome	0.000203	0.00141	CcSEcCtD
Ruxolitinib—Infestation—Topiramate—epilepsy syndrome	0.000203	0.00141	CcSEcCtD
Ruxolitinib—Flatulence—Pregabalin—epilepsy syndrome	0.000203	0.00141	CcSEcCtD
Ruxolitinib—Dizziness—Midazolam—epilepsy syndrome	0.000202	0.0014	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Lamotrigine—epilepsy syndrome	0.000202	0.0014	CcSEcCtD
Ruxolitinib—Body temperature increased—Clonazepam—epilepsy syndrome	0.000202	0.0014	CcSEcCtD
Ruxolitinib—TAOK3—nervous system—epilepsy syndrome	0.000202	0.00161	CbGeAlD
Ruxolitinib—Fatigue—Lamotrigine—epilepsy syndrome	0.000202	0.0014	CcSEcCtD
Ruxolitinib—Pruritus—Vigabatrin—epilepsy syndrome	0.000201	0.00139	CcSEcCtD
Ruxolitinib—Asthenia—Diazepam—epilepsy syndrome	0.000201	0.00139	CcSEcCtD
Ruxolitinib—Body temperature increased—Phenytoin—epilepsy syndrome	0.000201	0.00139	CcSEcCtD
Ruxolitinib—Dizziness—Levetiracetam—epilepsy syndrome	0.0002	0.00139	CcSEcCtD
Ruxolitinib—Body temperature increased—Oxcarbazepine—epilepsy syndrome	0.000199	0.00138	CcSEcCtD
Ruxolitinib—MAP3K2—brain—epilepsy syndrome	0.000198	0.00158	CbGeAlD
Ruxolitinib—Pruritus—Diazepam—epilepsy syndrome	0.000198	0.00137	CcSEcCtD
Ruxolitinib—Urinary tract infection—Topiramate—epilepsy syndrome	0.000198	0.00137	CcSEcCtD
Ruxolitinib—MAP3K7—brain—epilepsy syndrome	0.000196	0.00157	CbGeAlD
Ruxolitinib—Headache—Propofol—epilepsy syndrome	0.000196	0.00136	CcSEcCtD
Ruxolitinib—TAOK3—central nervous system—epilepsy syndrome	0.000194	0.00155	CbGeAlD
Ruxolitinib—Asthenia—Felbamate—epilepsy syndrome	0.000194	0.00135	CcSEcCtD
Ruxolitinib—Haematuria—Topiramate—epilepsy syndrome	0.000194	0.00135	CcSEcCtD
Ruxolitinib—TYK2—brain—epilepsy syndrome	0.000193	0.00154	CbGeAlD
Ruxolitinib—Dizziness—Fosphenytoin—epilepsy syndrome	0.000193	0.00134	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—epilepsy syndrome	0.000193	0.00134	CcSEcCtD
Ruxolitinib—Epistaxis—Topiramate—epilepsy syndrome	0.000192	0.00133	CcSEcCtD
Ruxolitinib—Headache—Midazolam—epilepsy syndrome	0.000192	0.00133	CcSEcCtD
Ruxolitinib—Pruritus—Felbamate—epilepsy syndrome	0.000192	0.00133	CcSEcCtD
Ruxolitinib—Body temperature increased—Carbamazepine—epilepsy syndrome	0.000191	0.00133	CcSEcCtD
Ruxolitinib—IRAK1—brain—epilepsy syndrome	0.00019	0.00152	CbGeAlD
Ruxolitinib—MKNK2—brain—epilepsy syndrome	0.00019	0.00152	CbGeAlD
Ruxolitinib—Anaemia—Pregabalin—epilepsy syndrome	0.00019	0.00132	CcSEcCtD
Ruxolitinib—Asthenia—Zonisamide—epilepsy syndrome	0.00019	0.00132	CcSEcCtD
Ruxolitinib—TAOK3—cerebellum—epilepsy syndrome	0.00019	0.00151	CbGeAlD
Ruxolitinib—Headache—Levetiracetam—epilepsy syndrome	0.000189	0.00131	CcSEcCtD
Ruxolitinib—Malnutrition—Gabapentin—epilepsy syndrome	0.000189	0.00131	CcSEcCtD
Ruxolitinib—Dizziness—Vigabatrin—epilepsy syndrome	0.000188	0.0013	CcSEcCtD
Ruxolitinib—Pruritus—Zonisamide—epilepsy syndrome	0.000187	0.0013	CcSEcCtD
Ruxolitinib—Flatulence—Gabapentin—epilepsy syndrome	0.000186	0.00129	CcSEcCtD
Ruxolitinib—RET—brain—epilepsy syndrome	0.000186	0.00148	CbGeAlD
Ruxolitinib—Body temperature increased—Lamotrigine—epilepsy syndrome	0.000185	0.00128	CcSEcCtD
Ruxolitinib—Dizziness—Diazepam—epilepsy syndrome	0.000185	0.00128	CcSEcCtD
Ruxolitinib—Infection—Valproic Acid—epilepsy syndrome	0.000185	0.00128	CcSEcCtD
Ruxolitinib—Haemoglobin—Topiramate—epilepsy syndrome	0.000183	0.00127	CcSEcCtD
Ruxolitinib—Asthenia—Clonazepam—epilepsy syndrome	0.000183	0.00127	CcSEcCtD
Ruxolitinib—Headache—Fosphenytoin—epilepsy syndrome	0.000183	0.00127	CcSEcCtD
Ruxolitinib—Haemorrhage—Topiramate—epilepsy syndrome	0.000183	0.00127	CcSEcCtD
Ruxolitinib—Nervous system disorder—Valproic Acid—epilepsy syndrome	0.000182	0.00127	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Valproic Acid—epilepsy syndrome	0.000182	0.00126	CcSEcCtD
Ruxolitinib—Asthenia—Phenytoin—epilepsy syndrome	0.000182	0.00126	CcSEcCtD
Ruxolitinib—Asthenia—Oxcarbazepine—epilepsy syndrome	0.000181	0.00126	CcSEcCtD
Ruxolitinib—Pruritus—Clonazepam—epilepsy syndrome	0.000181	0.00125	CcSEcCtD
Ruxolitinib—Skin disorder—Valproic Acid—epilepsy syndrome	0.000181	0.00125	CcSEcCtD
Ruxolitinib—Pruritus—Phenytoin—epilepsy syndrome	0.000179	0.00125	CcSEcCtD
Ruxolitinib—Dizziness—Felbamate—epilepsy syndrome	0.000179	0.00124	CcSEcCtD
Ruxolitinib—Pruritus—Oxcarbazepine—epilepsy syndrome	0.000179	0.00124	CcSEcCtD
Ruxolitinib—Headache—Vigabatrin—epilepsy syndrome	0.000178	0.00123	CcSEcCtD
Ruxolitinib—JAK2—brain—epilepsy syndrome	0.000176	0.0014	CbGeAlD
Ruxolitinib—Dizziness—Zonisamide—epilepsy syndrome	0.000175	0.00122	CcSEcCtD
Ruxolitinib—Headache—Diazepam—epilepsy syndrome	0.000175	0.00122	CcSEcCtD
Ruxolitinib—Anaemia—Gabapentin—epilepsy syndrome	0.000175	0.00121	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	0.000174	0.00121	CcSEcCtD
Ruxolitinib—Asthenia—Carbamazepine—epilepsy syndrome	0.000174	0.00121	CcSEcCtD
Ruxolitinib—Pruritus—Carbamazepine—epilepsy syndrome	0.000171	0.00119	CcSEcCtD
Ruxolitinib—Headache—Felbamate—epilepsy syndrome	0.00017	0.00118	CcSEcCtD
Ruxolitinib—MAP3K3—brain—epilepsy syndrome	0.000169	0.00135	CbGeAlD
Ruxolitinib—Dizziness—Clonazepam—epilepsy syndrome	0.000169	0.00117	CcSEcCtD
Ruxolitinib—Asthenia—Lamotrigine—epilepsy syndrome	0.000168	0.00116	CcSEcCtD
Ruxolitinib—Dizziness—Phenytoin—epilepsy syndrome	0.000168	0.00116	CcSEcCtD
Ruxolitinib—Infection—Pregabalin—epilepsy syndrome	0.000167	0.00116	CcSEcCtD
Ruxolitinib—Dizziness—Oxcarbazepine—epilepsy syndrome	0.000167	0.00116	CcSEcCtD
Ruxolitinib—Headache—Zonisamide—epilepsy syndrome	0.000166	0.00115	CcSEcCtD
Ruxolitinib—Pruritus—Lamotrigine—epilepsy syndrome	0.000166	0.00115	CcSEcCtD
Ruxolitinib—Nervous system disorder—Pregabalin—epilepsy syndrome	0.000165	0.00114	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Pregabalin—epilepsy syndrome	0.000165	0.00114	CcSEcCtD
Ruxolitinib—Skin disorder—Pregabalin—epilepsy syndrome	0.000163	0.00113	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	0.000161	0.00111	CcSEcCtD
Ruxolitinib—Fatigue—Valproic Acid—epilepsy syndrome	0.00016	0.00111	CcSEcCtD
Ruxolitinib—Dizziness—Carbamazepine—epilepsy syndrome	0.00016	0.00111	CcSEcCtD
Ruxolitinib—Headache—Clonazepam—epilepsy syndrome	0.00016	0.00111	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	0.00016	0.00111	CcSEcCtD
Ruxolitinib—Headache—Phenytoin—epilepsy syndrome	0.000159	0.0011	CcSEcCtD
Ruxolitinib—Malnutrition—Topiramate—epilepsy syndrome	0.000159	0.0011	CcSEcCtD
Ruxolitinib—Headache—Oxcarbazepine—epilepsy syndrome	0.000158	0.0011	CcSEcCtD
Ruxolitinib—Flatulence—Topiramate—epilepsy syndrome	0.000157	0.00109	CcSEcCtD
Ruxolitinib—Dizziness—Lamotrigine—epilepsy syndrome	0.000155	0.00107	CcSEcCtD
Ruxolitinib—TAOK3—brain—epilepsy syndrome	0.000154	0.00123	CbGeAlD
Ruxolitinib—Infection—Gabapentin—epilepsy syndrome	0.000153	0.00106	CcSEcCtD
Ruxolitinib—Headache—Carbamazepine—epilepsy syndrome	0.000152	0.00105	CcSEcCtD
Ruxolitinib—Nervous system disorder—Gabapentin—epilepsy syndrome	0.000151	0.00105	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Gabapentin—epilepsy syndrome	0.000151	0.00105	CcSEcCtD
Ruxolitinib—Skin disorder—Gabapentin—epilepsy syndrome	0.00015	0.00104	CcSEcCtD
Ruxolitinib—Body temperature increased—Valproic Acid—epilepsy syndrome	0.000147	0.00102	CcSEcCtD
Ruxolitinib—Anaemia—Topiramate—epilepsy syndrome	0.000147	0.00102	CcSEcCtD
Ruxolitinib—Headache—Lamotrigine—epilepsy syndrome	0.000147	0.00102	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	0.000145	0.00101	CcSEcCtD
Ruxolitinib—Fatigue—Pregabalin—epilepsy syndrome	0.000145	0.00101	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	0.000134	0.000932	CcSEcCtD
Ruxolitinib—Asthenia—Valproic Acid—epilepsy syndrome	0.000133	0.000926	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	0.000133	0.000923	CcSEcCtD
Ruxolitinib—Fatigue—Gabapentin—epilepsy syndrome	0.000133	0.000922	CcSEcCtD
Ruxolitinib—Body temperature increased—Pregabalin—epilepsy syndrome	0.000133	0.000922	CcSEcCtD
Ruxolitinib—Pruritus—Valproic Acid—epilepsy syndrome	0.000132	0.000913	CcSEcCtD
Ruxolitinib—Infection—Topiramate—epilepsy syndrome	0.000129	0.000894	CcSEcCtD
Ruxolitinib—Nervous system disorder—Topiramate—epilepsy syndrome	0.000127	0.000882	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Topiramate—epilepsy syndrome	0.000127	0.000881	CcSEcCtD
Ruxolitinib—Skin disorder—Topiramate—epilepsy syndrome	0.000126	0.000874	CcSEcCtD
Ruxolitinib—Dizziness—Valproic Acid—epilepsy syndrome	0.000123	0.000853	CcSEcCtD
Ruxolitinib—Body temperature increased—Gabapentin—epilepsy syndrome	0.000122	0.000846	CcSEcCtD
Ruxolitinib—Asthenia—Pregabalin—epilepsy syndrome	0.000121	0.000837	CcSEcCtD
Ruxolitinib—Pruritus—Pregabalin—epilepsy syndrome	0.000119	0.000825	CcSEcCtD
Ruxolitinib—Headache—Valproic Acid—epilepsy syndrome	0.000117	0.000808	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Topiramate—epilepsy syndrome	0.000112	0.000777	CcSEcCtD
Ruxolitinib—Fatigue—Topiramate—epilepsy syndrome	0.000112	0.000776	CcSEcCtD
Ruxolitinib—Dizziness—Pregabalin—epilepsy syndrome	0.000111	0.000771	CcSEcCtD
Ruxolitinib—Asthenia—Gabapentin—epilepsy syndrome	0.000111	0.000767	CcSEcCtD
Ruxolitinib—Pruritus—Gabapentin—epilepsy syndrome	0.000109	0.000757	CcSEcCtD
Ruxolitinib—Headache—Pregabalin—epilepsy syndrome	0.000105	0.000731	CcSEcCtD
Ruxolitinib—Body temperature increased—Topiramate—epilepsy syndrome	0.000103	0.000711	CcSEcCtD
Ruxolitinib—Dizziness—Gabapentin—epilepsy syndrome	0.000102	0.000707	CcSEcCtD
Ruxolitinib—Headache—Gabapentin—epilepsy syndrome	9.66e-05	0.00067	CcSEcCtD
Ruxolitinib—Asthenia—Topiramate—epilepsy syndrome	9.31e-05	0.000646	CcSEcCtD
Ruxolitinib—Pruritus—Topiramate—epilepsy syndrome	9.18e-05	0.000637	CcSEcCtD
Ruxolitinib—Dizziness—Topiramate—epilepsy syndrome	8.58e-05	0.000595	CcSEcCtD
Ruxolitinib—Headache—Topiramate—epilepsy syndrome	8.13e-05	0.000564	CcSEcCtD
Ruxolitinib—CYP3A4—nervous system—epilepsy syndrome	6.13e-05	0.000488	CbGeAlD
Ruxolitinib—CYP3A4—central nervous system—epilepsy syndrome	5.9e-05	0.00047	CbGeAlD
Ruxolitinib—CYP3A4—Metabolism—PFKL—epilepsy syndrome	1.86e-06	8.71e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLCO1A2—epilepsy syndrome	1.86e-06	8.71e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—KCNB1—epilepsy syndrome	1.86e-06	8.71e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—BCL2—epilepsy syndrome	1.86e-06	8.7e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—H2AFX—epilepsy syndrome	1.86e-06	8.7e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MEF2C—epilepsy syndrome	1.86e-06	8.68e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—POMC—epilepsy syndrome	1.85e-06	8.67e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—YWHAZ—epilepsy syndrome	1.85e-06	8.65e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—FGF2—epilepsy syndrome	1.85e-06	8.63e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCL2—epilepsy syndrome	1.84e-06	8.62e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCR5—epilepsy syndrome	1.83e-06	8.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HBEGF—epilepsy syndrome	1.83e-06	8.56e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NGF—epilepsy syndrome	1.83e-06	8.56e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—RELA—epilepsy syndrome	1.82e-06	8.51e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MMP9—epilepsy syndrome	1.82e-06	8.49e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCL2—epilepsy syndrome	1.81e-06	8.48e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—BCL2—epilepsy syndrome	1.81e-06	8.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—SRC—epilepsy syndrome	1.81e-06	8.44e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—RELA—epilepsy syndrome	1.8e-06	8.41e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT3—epilepsy syndrome	1.8e-06	8.4e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—YWHAZ—epilepsy syndrome	1.8e-06	8.39e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HTR2A—epilepsy syndrome	1.79e-06	8.39e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TSC2—epilepsy syndrome	1.79e-06	8.37e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PRKCB—epilepsy syndrome	1.79e-06	8.37e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—POMC—epilepsy syndrome	1.79e-06	8.35e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MTOR—epilepsy syndrome	1.78e-06	8.34e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6ST—epilepsy syndrome	1.78e-06	8.34e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCR5—epilepsy syndrome	1.78e-06	8.32e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NGF—epilepsy syndrome	1.78e-06	8.3e-06	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—AKT1—epilepsy syndrome	1.77e-06	8.29e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—RELA—epilepsy syndrome	1.77e-06	8.26e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MTOR—epilepsy syndrome	1.76e-06	8.25e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—AKT1—epilepsy syndrome	1.76e-06	8.24e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—FGF2—epilepsy syndrome	1.76e-06	8.21e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ADAM10—epilepsy syndrome	1.75e-06	8.2e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—APOE—epilepsy syndrome	1.75e-06	8.19e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—BCL2—epilepsy syndrome	1.75e-06	8.19e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CCL2—epilepsy syndrome	1.75e-06	8.17e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HTR2A—epilepsy syndrome	1.74e-06	8.14e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—SRC—epilepsy syndrome	1.74e-06	8.12e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MTOR—epilepsy syndrome	1.73e-06	8.1e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCR5—epilepsy syndrome	1.73e-06	8.07e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—RELA—epilepsy syndrome	1.71e-06	8.01e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TNF—epilepsy syndrome	1.71e-06	7.98e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TSC2—epilepsy syndrome	1.71e-06	7.97e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NEU1—epilepsy syndrome	1.7e-06	7.97e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ATIC—epilepsy syndrome	1.7e-06	7.97e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—UPB1—epilepsy syndrome	1.7e-06	7.97e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AGT—epilepsy syndrome	1.7e-06	7.96e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HTR2A—epilepsy syndrome	1.69e-06	7.9e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MTOR—epilepsy syndrome	1.68e-06	7.86e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—AKT1—epilepsy syndrome	1.68e-06	7.84e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—SRC—epilepsy syndrome	1.67e-06	7.83e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—APOE—epilepsy syndrome	1.67e-06	7.8e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—FGF2—epilepsy syndrome	1.67e-06	7.79e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—S100B—epilepsy syndrome	1.66e-06	7.76e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TSC2—epilepsy syndrome	1.66e-06	7.74e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AGT—epilepsy syndrome	1.65e-06	7.73e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6ST—epilepsy syndrome	1.65e-06	7.7e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL1B—epilepsy syndrome	1.65e-06	7.69e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SOCS3—epilepsy syndrome	1.64e-06	7.68e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HSD17B4—epilepsy syndrome	1.64e-06	7.67e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—FGF2—epilepsy syndrome	1.64e-06	7.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDC42—epilepsy syndrome	1.64e-06	7.66e-06	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—AKT1—epilepsy syndrome	1.64e-06	7.65e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KDR—epilepsy syndrome	1.63e-06	7.64e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—FOS—epilepsy syndrome	1.63e-06	7.64e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOS2—epilepsy syndrome	1.63e-06	7.64e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—VEGFA—epilepsy syndrome	1.63e-06	7.63e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CASP3—epilepsy syndrome	1.62e-06	7.58e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—APOE—epilepsy syndrome	1.62e-06	7.57e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—AKT1—epilepsy syndrome	1.61e-06	7.53e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TSC2—epilepsy syndrome	1.61e-06	7.5e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AGT—epilepsy syndrome	1.6e-06	7.5e-06	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—AKT1—epilepsy syndrome	1.6e-06	7.49e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MTOR—epilepsy syndrome	1.6e-06	7.48e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL1B—epilepsy syndrome	1.6e-06	7.47e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CASP8—epilepsy syndrome	1.6e-06	7.46e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—JUN—epilepsy syndrome	1.59e-06	7.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AVP—epilepsy syndrome	1.59e-06	7.42e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KDR—epilepsy syndrome	1.59e-06	7.42e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—epilepsy syndrome	1.59e-06	7.41e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GBE1—epilepsy syndrome	1.58e-06	7.41e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPP1R3C—epilepsy syndrome	1.58e-06	7.41e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—JUN—epilepsy syndrome	1.58e-06	7.37e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PRKCB—epilepsy syndrome	1.57e-06	7.36e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APOE—epilepsy syndrome	1.57e-06	7.34e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6ST—epilepsy syndrome	1.57e-06	7.33e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL1B—epilepsy syndrome	1.55e-06	7.24e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—JUN—epilepsy syndrome	1.55e-06	7.24e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—RELA—epilepsy syndrome	1.55e-06	7.23e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KDR—epilepsy syndrome	1.54e-06	7.2e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MMP9—epilepsy syndrome	1.53e-06	7.17e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PRKCB—epilepsy syndrome	1.53e-06	7.14e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—AKT1—epilepsy syndrome	1.53e-06	7.13e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—RELA—epilepsy syndrome	1.52e-06	7.11e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6ST—epilepsy syndrome	1.52e-06	7.11e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MTOR—epilepsy syndrome	1.52e-06	7.09e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—JUN—epilepsy syndrome	1.5e-06	7.02e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HES1—epilepsy syndrome	1.5e-06	7.01e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MTOR—epilepsy syndrome	1.49e-06	6.98e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ASAH1—epilepsy syndrome	1.49e-06	6.96e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—AKT1—epilepsy syndrome	1.49e-06	6.95e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—AKT1—epilepsy syndrome	1.49e-06	6.95e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PRKCB—epilepsy syndrome	1.48e-06	6.93e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—AKT1—epilepsy syndrome	1.48e-06	6.92e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6ST—epilepsy syndrome	1.48e-06	6.9e-06	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—AKT1—epilepsy syndrome	1.47e-06	6.89e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FYN—epilepsy syndrome	1.46e-06	6.82e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—H2AFX—epilepsy syndrome	1.45e-06	6.8e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MEF2C—epilepsy syndrome	1.45e-06	6.78e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	1.45e-06	6.77e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—FGF2—epilepsy syndrome	1.44e-06	6.74e-06	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—AKT1—epilepsy syndrome	1.44e-06	6.73e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—AKT1—epilepsy syndrome	1.44e-06	6.72e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—POMC—epilepsy syndrome	1.43e-06	6.7e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—SRC—epilepsy syndrome	1.43e-06	6.69e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—SRC—epilepsy syndrome	1.41e-06	6.61e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NT5E—epilepsy syndrome	1.41e-06	6.6e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALAD—epilepsy syndrome	1.41e-06	6.6e-06	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—AKT1—epilepsy syndrome	1.41e-06	6.58e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—YWHAZ—epilepsy syndrome	1.4e-06	6.56e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCL2—epilepsy syndrome	1.4e-06	6.56e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CASP3—epilepsy syndrome	1.4e-06	6.52e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—POMC—epilepsy syndrome	1.39e-06	6.5e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—SRC—epilepsy syndrome	1.39e-06	6.49e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NGF—epilepsy syndrome	1.39e-06	6.48e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—AKT1—epilepsy syndrome	1.39e-06	6.48e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—AKT1—epilepsy syndrome	1.38e-06	6.45e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—epilepsy syndrome	1.38e-06	6.44e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CASP3—epilepsy syndrome	1.37e-06	6.42e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—BCL2—epilepsy syndrome	1.37e-06	6.4e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCL2—epilepsy syndrome	1.36e-06	6.36e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—AKT1—epilepsy syndrome	1.36e-06	6.35e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—JUN—epilepsy syndrome	1.36e-06	6.34e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—POMC—epilepsy syndrome	1.35e-06	6.31e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCR5—epilepsy syndrome	1.35e-06	6.31e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	1.35e-06	6.3e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	1.35e-06	6.3e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—SRC—epilepsy syndrome	1.35e-06	6.29e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—RELA—epilepsy syndrome	1.34e-06	6.26e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—JUN—epilepsy syndrome	1.33e-06	6.23e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—FGF2—epilepsy syndrome	1.33e-06	6.23e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCL2—epilepsy syndrome	1.32e-06	6.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HTR2A—epilepsy syndrome	1.32e-06	6.17e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—epilepsy syndrome	1.32e-06	6.17e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	1.32e-06	6.16e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MTOR—epilepsy syndrome	1.31e-06	6.14e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—epilepsy syndrome	1.3e-06	6.06e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADSL—epilepsy syndrome	1.29e-06	6.04e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—SRC—epilepsy syndrome	1.28e-06	5.99e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—AKT1—epilepsy syndrome	1.28e-06	5.98e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—epilepsy syndrome	1.27e-06	5.94e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FGF2—epilepsy syndrome	1.27e-06	5.93e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GLUL—epilepsy syndrome	1.27e-06	5.92e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—epilepsy syndrome	1.26e-06	5.88e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TSC2—epilepsy syndrome	1.25e-06	5.86e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AGT—epilepsy syndrome	1.25e-06	5.86e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—epilepsy syndrome	1.25e-06	5.83e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	1.24e-06	5.81e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FGF2—epilepsy syndrome	1.23e-06	5.75e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOE—epilepsy syndrome	1.23e-06	5.74e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—SRC—epilepsy syndrome	1.22e-06	5.68e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MTOR—epilepsy syndrome	1.21e-06	5.67e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1B—epilepsy syndrome	1.21e-06	5.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KDR—epilepsy syndrome	1.2e-06	5.62e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—epilepsy syndrome	1.2e-06	5.62e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—SRC—epilepsy syndrome	1.2e-06	5.59e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FGF2—epilepsy syndrome	1.19e-06	5.58e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—epilepsy syndrome	1.18e-06	5.54e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—RELA—epilepsy syndrome	1.18e-06	5.5e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—JUN—epilepsy syndrome	1.17e-06	5.48e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—epilepsy syndrome	1.17e-06	5.46e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—epilepsy syndrome	1.16e-06	5.44e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	1.16e-06	5.44e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PRKCB—epilepsy syndrome	1.16e-06	5.41e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MTOR—epilepsy syndrome	1.15e-06	5.39e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6ST—epilepsy syndrome	1.15e-06	5.39e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RELA—epilepsy syndrome	1.14e-06	5.34e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AQP1—epilepsy syndrome	1.13e-06	5.28e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—epilepsy syndrome	1.12e-06	5.25e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MTOR—epilepsy syndrome	1.12e-06	5.24e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RELA—epilepsy syndrome	1.11e-06	5.18e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MTOR—epilepsy syndrome	1.09e-06	5.08e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—epilepsy syndrome	1.08e-06	5.04e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—epilepsy syndrome	1.06e-06	4.96e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—POMC—epilepsy syndrome	1.05e-06	4.93e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—SRC—epilepsy syndrome	1.05e-06	4.92e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—epilepsy syndrome	1.04e-06	4.87e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL2—epilepsy syndrome	1.03e-06	4.82e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—JUN—epilepsy syndrome	1.03e-06	4.82e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—epilepsy syndrome	1.03e-06	4.82e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	1.02e-06	4.77e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	1.02e-06	4.77e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—epilepsy syndrome	1e-06	4.69e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—JUN—epilepsy syndrome	1e-06	4.68e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—epilepsy syndrome	9.99e-07	4.67e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—epilepsy syndrome	9.74e-07	4.55e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SRC—epilepsy syndrome	9.72e-07	4.54e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—JUN—epilepsy syndrome	9.71e-07	4.54e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—epilepsy syndrome	9.44e-07	4.41e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—epilepsy syndrome	9.44e-07	4.41e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGF2—epilepsy syndrome	9.33e-07	4.36e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SRC—epilepsy syndrome	9.25e-07	4.32e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—epilepsy syndrome	9.01e-07	4.21e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SRC—epilepsy syndrome	8.98e-07	4.2e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—epilepsy syndrome	8.89e-07	4.15e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—epilepsy syndrome	8.78e-07	4.11e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—epilepsy syndrome	8.74e-07	4.09e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SRC—epilepsy syndrome	8.71e-07	4.07e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RELA—epilepsy syndrome	8.66e-07	4.05e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—epilepsy syndrome	8.63e-07	4.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MTOR—epilepsy syndrome	8.49e-07	3.97e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—epilepsy syndrome	8.48e-07	3.96e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—epilepsy syndrome	8.37e-07	3.91e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	8.32e-07	3.89e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	8.11e-07	3.79e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	8.06e-07	3.77e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—epilepsy syndrome	7.97e-07	3.72e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—epilepsy syndrome	7.88e-07	3.68e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—epilepsy syndrome	7.81e-07	3.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—JUN—epilepsy syndrome	7.58e-07	3.55e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—epilepsy syndrome	7.56e-07	3.53e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—epilepsy syndrome	7.43e-07	3.47e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—epilepsy syndrome	7.38e-07	3.45e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	7.28e-07	3.4e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—epilepsy syndrome	7.16e-07	3.35e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	6.93e-07	3.24e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—BCHE—epilepsy syndrome	6.9e-07	3.22e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SRC—epilepsy syndrome	6.8e-07	3.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—epilepsy syndrome	6.63e-07	3.1e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	6.58e-07	3.08e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—epilepsy syndrome	6.54e-07	3.06e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	6.51e-07	3.04e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TH—epilepsy syndrome	6.49e-07	3.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—epilepsy syndrome	6.04e-07	2.82e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—epilepsy syndrome	5.75e-07	2.69e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—epilepsy syndrome	5.58e-07	2.61e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	5.41e-07	2.53e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—epilepsy syndrome	5.41e-07	2.53e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CAT—epilepsy syndrome	5.34e-07	2.5e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	5.2e-07	2.43e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX1—epilepsy syndrome	4.83e-07	2.26e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AGT—epilepsy syndrome	4.24e-07	1.98e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—epilepsy syndrome	4.23e-07	1.98e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOE—epilepsy syndrome	4.15e-07	1.94e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—POMC—epilepsy syndrome	3.56e-07	1.67e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—epilepsy syndrome	3.25e-07	1.52e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	2.84e-07	1.33e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—epilepsy syndrome	1.43e-07	6.68e-07	CbGpPWpGaD
